1. Fig. 1. Trial profile.
From: Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the Reduction in New Vertebral Fractures in Subjects with Primary Osteoporosis and High Fracture Risk
J Clin Endocrinol Metab. 2012;97(9): doi: /jc
J Clin Endocrinol Metab | Copyright © 2012 by The Endocrine Society

2. Fig. 2. Incidence of new fractures during the 72-wk study period was confirmed by radiology. A, Kaplan-Meier method, statistical significance assessed by a log-rank test. RR, Relative risk. B, Incidence values of new vertebral fractures assessed every 24 wk by Fisher's exact test. 95% CI is presented for the results of fracture incidences. C, Incidences of clinical fragility fracture in the teriparatide group were significantly reduced compared with placebo.
From: Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the Reduction in New Vertebral Fractures in Subjects with Primary Osteoporosis and High Fracture Risk
J Clin Endocrinol Metab. 2012;97(9): doi: /jc
J Clin Endocrinol Metab | Copyright © 2012 by The Endocrine Society

3. Fig. 3. Changes over time in BMD and biochemical markers
Fig. 3. Changes over time in BMD and biochemical markers. For the BMD analysis, the difference in percentage changes from baseline was compared between the teriparatide and placebo groups for the bone turnover markers. A, Lumbar spine BMD; B, total hip BMD; C, serum osteocalcin; D, serum P1NP; E, u-NTX; and F, corrected serum calcium. A comparison was performed using a paired t test with the Wilcoxon test; bars indicate 95% CI.
From: Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the Reduction in New Vertebral Fractures in Subjects with Primary Osteoporosis and High Fracture Risk
J Clin Endocrinol Metab. 2012;97(9): doi: /jc
J Clin Endocrinol Metab | Copyright © 2012 by The Endocrine Society